DAAC
Dead / Abandoned — Abandoned — no statement of use filed (as of 03 Sept 2018)
What this means for you
This application is over — abandoned 03 Sept 2018. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87519652
- Mark type
- Stylized text
- Filed
- 07 Jul 2017
- Published for opposition
- 05 Dec 2017
- Abandoned
- 03 Sept 2018
- Attorney of record
- Christina M. Licursi, Esq.
Goods and services
- Class 001 — Chemicals: Chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for use in scientific and medical research; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, and nutrients and nutritive products for use in the manufacture of beverages, food products and food supplements for human and non-human use; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for use in the manufacture of pharmaceutical preparations, medicines, medical foods, nutraceuticals, and dietary and nutritional foods and supplements; chemical and biochemical compounds, proteins, polypeptides, peptides, amino acids, vitamins, minerals, and nutrients and nutritive products being an ingredient in the manufacture of pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, and muscle, bones, joints, and whole body movement; chemical and biochemical compounds, proteins, polypeptides, peptides, amino acids, vitamins, minerals, and nutrients and nutritive products being an ingredient in the manufacture of pharmaceutical preparations for the treatment or prevention of muscle loss, metabolic conditions and diseases, gastrointestinal conditions and diseases, neurological conditions and diseases, cancer, osteoporosis, inflammatory conditions and diseases, genetic conditions and diseases, muscle diseases and disorders, hepatic conditions and diseases, fibrosis, malnutrition, atrophic diseases and conditions, epilepsy, sarcopenia, myopathies, neuropathies, neurodegenerative diseases, traumatic brain injury, concussion, movement disorders, dystrophies, anemias, and orphan diseases; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for in vitro medical research and in vivo scientific research
- Class 005 — Pharmaceuticals: pharmaceutical preparations and agents for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; proteins, polypeptides, peptides, amino acids, and small molecules being a featured component of pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; medicines, namely, proteins, biomolecules in the nature of polypeptides and peptides, amino acids, and small molecules in the nature of organic compounds and amino acid metabolites for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; medical foods, namely, food that is intended for the specific dietary management of a disease or condition; nutraceuticals for treating or restoring health in patients with diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; dietary and nutritional supplements
Owner
- Axcella Health Inc., Cambridge, MA, US
- Axcella Health Inc., Cambridge, MA, US
Prosecution history
- 04 Sept 2018 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
- 03 Sept 2018 — ABANDONMENT - NO USE STATEMENT FILED
- 30 Jan 2018 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Dec 2017 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Dec 2017 — PUBLISHED FOR OPPOSITION
- 15 Nov 2017 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Oct 2017 — ASSIGNED TO LIE
- 11 Oct 2017 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Oct 2017 — EXAMINER'S AMENDMENT ENTERED
- 11 Oct 2017 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Oct 2017 — EXAMINERS AMENDMENT E-MAILED
- 11 Oct 2017 — EXAMINERS AMENDMENT -WRITTEN
- 06 Oct 2017 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 06 Oct 2017 — NON-FINAL ACTION E-MAILED
- 06 Oct 2017 — NON-FINAL ACTION WRITTEN